{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:33Z","timestamp":1761895473185},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.006","type":"journal-article","created":{"date-parts":[[2012,5,12]],"date-time":"2012-05-12T02:31:49Z","timestamp":1336789909000},"page":"221-231","source":"Crossref","is-referenced-by-count":7,"title":["Management of mantle cell lymphoma in the elderly"],"prefix":"10.1016","volume":"25","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Till","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2012.04.006_bib1","unstructured":"Chandran R, Gardiner SK, Simon M, Spurgeon SE. Survival trends in Mantle cell lymphoma in the United States over sixteen years 1992\u20132007. Leukemia & Lymphoma;0:1\u201318."},{"key":"10.1016\/j.beha.2012.04.006_bib2","unstructured":"Roughly 55% of cancer diagnoses occur in patients older than 65 years. SEER cancer statistics review, 1975\u20132005 (National Cancer Institute). [accessed at 29.04.12]"},{"key":"10.1016\/j.beha.2012.04.006_bib3","series-title":"The 2012 statistical abstract","year":"2012"},{"key":"10.1016\/j.beha.2012.04.006_bib4","series-title":"Ageing in the eighties: the prevalence of comorbidity and its association with disability. Advance data from vital and health statistics","author":"Guralnik","year":"1989"},{"key":"10.1016\/j.beha.2012.04.006_bib5","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.2010.31.6695","article-title":"Association of cancer with geriatric syndromes in older medicare beneficiaries","volume":"29","author":"Mohile","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib6","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mdr146","article-title":"Toxicity burden score: a novel approach to summarize multiple toxic effects","volume":"23","author":"Lee","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the mantle cell lymphoma International prognostic index in a population-based setting","volume":"95","author":"van de Schans","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.006_bib11","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib12","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib13","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.006_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2012.04.006_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib16","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not Influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss group for clinical cancer research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib19","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a Systematic Review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2012.04.006_bib21","first-page":"440","article-title":"The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the Randomised UK National cancer research Institute (NCRI) trial","volume":"118","author":"Rule","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib24","first-page":"439","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-Alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma","volume":"118","author":"Kluin-Nelemans","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib25","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clinical Oncology"},{"key":"10.1016\/j.beha.2012.04.006_bib26","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-Cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib27","doi-asserted-by":"crossref","first-page":"A2596","DOI":"10.1182\/blood.V112.11.2596.2596","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL)","volume":"112","author":"Rummel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib28","first-page":"2700","article-title":"Lenalidomide, bendamustine, and rituximab as first-line therapy for patients >65 Years with mantle cell lymphoma: results from the phase I portion of the Nordic lymphoma group MCL4 (LENA-BERIT) trial","volume":"118","author":"Jerkeman","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib29","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS","author":"Houot","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib30","first-page":"2677","article-title":"Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant","volume":"118","author":"Visco","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib31","first-page":"1647","article-title":"Safety, Tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study","volume":"118","author":"Magni","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.006_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.006_bib36","first-page":"9999","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.006_bib37","first-page":"387","article-title":"A multi center trial of hyperCVAD\u00a0+\u00a0Rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.006_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.006_bib39","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib40","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.006_bib41","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.006_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib43","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/10428190290026286","article-title":"Autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"43","author":"Oinonen","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.006_bib44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.006_bib45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and bone marrow transplant and autologous blood and marrow transplant registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.006_bib46","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.006_bib47","series-title":"Mantle cell lymphoma: results of the MCL younger trial of the European mantle cell lymphoma Network (MCL net)","first-page":"110","volume":"vol. 116","author":"Hermine","year":"2010"},{"key":"10.1016\/j.beha.2012.04.006_bib48","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib49","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)","author":"Jantunen","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib50","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bmt.1705371","article-title":"Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma","volume":"37","author":"Buadi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.006_bib51","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/annonc\/mdm608","article-title":"High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age","volume":"19","author":"Hosing","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib52","first-page":"iv86","article-title":"Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL): 5 year follow-up of Easter Cooperative Group E1499","volume":"22","author":"Smith","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib53","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib54","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib55","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.580404","article-title":"Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.006_bib57","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of Yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib58","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib59","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to Evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib60","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib61","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.006_bib62","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib63","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2\u00a0Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2147.2147","article-title":"Sustained graft-versus-lymphoma effect among patients (pts) with Mantle Cell Lymphoma (MCL) given Nonmyeloablative allogeneic Hematopoietic Cell Transplantation (HCT)","volume":"112","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib65","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.006_bib66","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.006_bib67","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.25756","article-title":"Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma","volume":"117","author":"Dietrich","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.006_bib68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.006_bib69","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.006_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T14:05:20Z","timestamp":1594130720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1521692612000333"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}